Table 2. Anti-PD-1/L1 agents: clinical data from phase II/III clinical trials.

Anti-PD-1/L1	Phase	Pts	ORR	Disease	Grade3–4 AE	Median PFS (Mo)	1-year OS	Reference
Nivolumab	2	168	20	RCC	17	4.2 (10 mg kg−1)	NR	Motzer et al (2014b)
Nivolumab	2	117	15	NSCLC	17.1		41
Nivolumab	3	418	40	MM	11.7	5.1	NR	Robert et al (2014)
Nivolumab	3	268	32	MM	9	NR	NR	Weber et al (2014)
Pembrolizumab	2	540	21 (2 mg kg−1) 25 (10 mg kg−1)	MM ipi refractory	11 (2 mg kg−1) 14 (10 mg kg−1)	2.9 (2 mg kg−1) 2.9 (10 mg kg−1)	NR	Ribas et al (2014b)
Pidilizumab	2	103	5.9	MM		2.8	64.5	Atkins et al (2014)
Pidilizumab+Rituximab	2	30	66	FL	0	21.1	NR	Westin et al (2010)

Abbreviations: AE=adverse events (%); MM=metastatic melanoma; NR=not reported; NSCLC=non-small-cell lung cancer; ORR=overall response rate (%); PD-1/L-1=programmed cell death protein-1 or its ligand; PFS=progression-free survival (months); Pts=patients; RCC=renal cell carcinoma; 1-year OS=years overall survival (%).